Shape Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Shape Therapeutics's estimated annual revenue is currently $34.5M per year.
- Shape Therapeutics's estimated revenue per employee is $193,750
- Shape Therapeutics's total funding is $148M.
Employee Data
- Shape Therapeutics has 178 Employees.
- Shape Therapeutics grew their employee count by 23% last year.
Shape Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Co-FOUNDER - Chairman SAB | Reveal Email/Phone |
2 | Co-Founder | Reveal Email/Phone |
3 | EVP, Preclinical Development | Reveal Email/Phone |
4 | VP, Head Process and Product Development | Reveal Email/Phone |
5 | VP, People Operations | Reveal Email/Phone |
6 | General Counsel | Reveal Email/Phone |
7 | VP Finance | Reveal Email/Phone |
8 | Senior Director, Head Pipeline Research | Reveal Email/Phone |
9 | Chief Scientific Officer | Reveal Email/Phone |
10 | Associate Director, Lab and Facilities Operations | Reveal Email/Phone |
Shape Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $0.9M | 6 | 0% | N/A | N/A |
#2 | $0.9M | 6 | 0% | N/A | N/A |
#3 | $5.1M | 33 | 6% | N/A | N/A |
#4 | $5.7M | 37 | 42% | N/A | N/A |
#5 | $1.4M | 18 | -10% | N/A | N/A |
#6 | $3.7M | 48 | -21% | $16M | N/A |
#7 | $1.1M | 7 | 0% | N/A | N/A |
#8 | $0.8M | 5 | -81% | N/A | N/A |
#9 | $2.5M | 16 | -27% | N/A | N/A |
#10 | $0.8M | 5 | -17% | N/A | N/A |
What Is Shape Therapeutics?
Shape Therapeutics (ShapeTx) is a development-stage biotechnology company establishing itself as the leader in next-generation gene therapy. Our novel technology platform enables direct in vivo targeting/modification of RNA by leveraging ADARs (Adenosine Deaminase Acting on RNA), suppressor tRNAs, and immune-stealth adeno-associated viruses (AAVs). ShapeTx is providing solutions to many of the challenges that contemporary genome engineering technologies face (like CRISPR, TALENs, etc.), such as permanent off-target damage, high risk of immunogenicity and therefore low in vivo applicability as effective gene therapy approaches. ShapeTxￃﾢ￢ﾂﾬ￢ﾄﾢs technology instead engages natural human cellular machinery to target RNA with high in vivo efficiency. Shape Genome, Shape Life!
keywords:N/A
$148M
Total Funding
178
Number of Employees
$34.5M
Revenue (est)
23%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Shape Therapeutics News
Global Peptide Therapeutics Market & Clinical Trials Insight 2028 ... is determined by the amino acid sequences and shape of the peptides.
... Novo Nordisk, Omeros Corporation, InBios International, Inc., Lyell Immunopharma, Inc., Shape Therapeutics and Tableau.
Shape Therapeutics has raised $112 million in a Series B co-led by Decheng Capital and Breton Capital. The Seattle-based company is a developer of RNA targeting, editing and replacement technologies intended to treat neurodegenerative disorders and rare genetic diseases. Shape Therapeutics was v ...
SEATTLE, July 15, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (ShapeTX), a biotechnology company developing RNA technologies to shape the future of gene therapy, today announced the completion of a $112 million Series B financing round co-led by Decheng Capital and Breton Capital, with part ...
The company describes its technology, RNAfix, as allowing for direct in vivo targeting and modification of RNA by using engineered adeno-associated viruses, suppressor tRNAs and proteins like adenosine deaminases acting on RNA, or ADARs. ShapeTx further said that RNAfix differentiates from othe ...
Other Companies in Seattle
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $69.1M | 178 | 46% | N/A |
#2 | $23.6M | 179 | 7% | N/A |
#3 | $15M | 179 | 7% | N/A |
#4 | $63.6M | 179 | N/A | N/A |
#5 | $7.5M | 179 | -10% | N/A |